tetano
Editor, Senior Moderator
Virology. 2017 Aug 25;511:135-141. doi: 10.1016/j.virol.2017.08.024. [Epub ahead of print]
[h=1]Pathogenicity testing of influenza candidate vaccine viruses in the ferret model.[/h] Belser JA[SUP]1[/SUP], Johnson A[SUP]1[/SUP], Pulit-Penaloza JA[SUP]1[/SUP], Pappas C[SUP]1[/SUP], Pearce MB[SUP]1[/SUP], Tzeng WP[SUP]1[/SUP], Hossain MJ[SUP]1[/SUP], Ridenour C[SUP]1[/SUP], Wang L[SUP]1[/SUP], Chen LM[SUP]1[/SUP], Wentworth DE[SUP]1[/SUP], Katz JM[SUP]1[/SUP], Maines TR[SUP]1[/SUP], Tumpey TM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The development of influenza candidate vaccine viruses (CVVs) for pre-pandemic vaccine production represents a critical step in pandemic preparedness. The multiple subtypes and clades of avian or swine origin influenza viruses circulating world-wide at any one time necessitates the continuous generation of CVVs to provide an advanced starting point should a novel zoonotic virus cross the species barrier and cause a pandemic. Furthermore, the evolution and diversity of novel influenza viruses that cause zoonotic infections requires ongoing monitoring and surveillance, and, when a lack of antigenic match between circulating viruses and available CVVs is identified, the production of new CVVs. Pandemic guidelines developed by the WHO Global Influenza Program govern the design and preparation of reverse genetics-derived CVVs, which must undergo numerous safety and quality tests prior to human use. Confirmation of reassortant CVV attenuation of virulence in ferrets relative to wild-type virus represents one of these critical steps, yet there is a paucity of information available regarding the relative degree of attenuation achieved by WHO-recommended CVVs developed against novel viruses with pandemic potential. To better understand the degree of CVV attenuation in the ferret model, we examined the relative virulence of six A/Puerto Rico/8/1934-based CVVs encompassing five different influenza A subtypes (H2N3, H5N1, H5N2, H5N8, and H7N9) compared with the respective wild-type virus in ferrets. Despite varied virulence of wild-type viruses in the ferret, all CVVs examined showed reductions in morbidity and viral shedding in upper respiratory tract tissues. Furthermore, unlike the wild-type counterparts, none of the CVVs spread to extrapulmonary tissues during the acute phase of infection. While the magnitude of virus attenuation varied between virus subtypes, collectively we show the reliable and reproducible attenuation of CVVs that have the A/Puerto Rico/9/1934 backbone in a mammalian model.
Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Ferret; Influenza; Pathogenicity; Vaccine viruses
PMID: 28846898 DOI: 10.1016/j.virol.2017.08.024
[h=1]Pathogenicity testing of influenza candidate vaccine viruses in the ferret model.[/h] Belser JA[SUP]1[/SUP], Johnson A[SUP]1[/SUP], Pulit-Penaloza JA[SUP]1[/SUP], Pappas C[SUP]1[/SUP], Pearce MB[SUP]1[/SUP], Tzeng WP[SUP]1[/SUP], Hossain MJ[SUP]1[/SUP], Ridenour C[SUP]1[/SUP], Wang L[SUP]1[/SUP], Chen LM[SUP]1[/SUP], Wentworth DE[SUP]1[/SUP], Katz JM[SUP]1[/SUP], Maines TR[SUP]1[/SUP], Tumpey TM[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The development of influenza candidate vaccine viruses (CVVs) for pre-pandemic vaccine production represents a critical step in pandemic preparedness. The multiple subtypes and clades of avian or swine origin influenza viruses circulating world-wide at any one time necessitates the continuous generation of CVVs to provide an advanced starting point should a novel zoonotic virus cross the species barrier and cause a pandemic. Furthermore, the evolution and diversity of novel influenza viruses that cause zoonotic infections requires ongoing monitoring and surveillance, and, when a lack of antigenic match between circulating viruses and available CVVs is identified, the production of new CVVs. Pandemic guidelines developed by the WHO Global Influenza Program govern the design and preparation of reverse genetics-derived CVVs, which must undergo numerous safety and quality tests prior to human use. Confirmation of reassortant CVV attenuation of virulence in ferrets relative to wild-type virus represents one of these critical steps, yet there is a paucity of information available regarding the relative degree of attenuation achieved by WHO-recommended CVVs developed against novel viruses with pandemic potential. To better understand the degree of CVV attenuation in the ferret model, we examined the relative virulence of six A/Puerto Rico/8/1934-based CVVs encompassing five different influenza A subtypes (H2N3, H5N1, H5N2, H5N8, and H7N9) compared with the respective wild-type virus in ferrets. Despite varied virulence of wild-type viruses in the ferret, all CVVs examined showed reductions in morbidity and viral shedding in upper respiratory tract tissues. Furthermore, unlike the wild-type counterparts, none of the CVVs spread to extrapulmonary tissues during the acute phase of infection. While the magnitude of virus attenuation varied between virus subtypes, collectively we show the reliable and reproducible attenuation of CVVs that have the A/Puerto Rico/9/1934 backbone in a mammalian model.
Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Ferret; Influenza; Pathogenicity; Vaccine viruses
PMID: 28846898 DOI: 10.1016/j.virol.2017.08.024